STOCK TITAN
  1. Home
  2. Sec-filings
  3. PBLS
  4. [Form 3] Parabilis Medicines, Inc. Initial Statement of Beneficial Ownership

Parabilis Medicines (PBLS) CEO Mammen Mathai details sizeable stock option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Parabilis Medicines, Inc. director and President & CEO Mammen Mathai filed an initial ownership report detailing several stock option awards over common stock. The filing lists options with exercise prices of $1.48, $3.14, and $3.43 per share, expiring between 2033 and 2036. Footnotes explain that these options vest in monthly installments, in some cases starting in March 2024 and February 2026, with one grant also contingent on achieving specified performance objectives and continued service.

Positive

  • None.

Negative

  • None.
Insider Mammen Mathai
Role President & CEO
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
Holdings After Transaction: Stock Option (right to buy) — 2,377,201 shares (Direct, null)
Footnotes (1)
  1. 25% of the shares subject to this option vested and became exercisable on March 16, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024 contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
Option exercise price $3.14 per share Stock option over common stock, expires February 23, 2036
Underlying shares at $3.14 2,274,351 shares Underlying common stock for $3.14 option grant
Option exercise price $1.48 per share Two stock option grants, expire March 27, 2034
Underlying shares at $1.48 590,940 shares First $1.48 option block, time-based vesting
Underlying shares at $1.48 (performance) 592,463 shares Second $1.48 option block, performance-contingent vesting
Option exercise price $3.43 per share Stock option expiring April 20, 2033
Underlying shares at $3.43 2,377,201 shares Underlying common shares for $3.43 option grant
Initial cliff vesting 25% vested March 16, 2024 Portion of one option grant vesting before monthly installments
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
underlying common stock financial
"underlying_security_title": "Common Stock""
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable in forty-eight"
performance objectives financial
"contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service"
continued service financial
"subject to the Reporting Person's continued service on each such vesting date"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Mammen Mathai
(Last)(First)(Middle)
C/O PARABILIS MEDICINES, INC.
30 ACORN PARK DRIVE, 6TH FLOOR
(Street)
CAMBRIDGE MASSACHUSETTS 02140
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026		3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
XOfficer (give title below)Other (specify below)
President & CEO
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1)04/20/2033Common Stock2,377,201$3.43D
Stock Option (right to buy) (2)03/27/2034Common Stock592,463$1.48D
Stock Option (right to buy) (3)03/27/2034Common Stock590,940$1.48D
Stock Option (right to buy) (4)02/23/2036Common Stock2,274,351$3.14D
Explanation of Responses:
1. 25% of the shares subject to this option vested and became exercisable on March 16, 2024 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024, subject to the Reporting Person's continued service on each such vesting date.
3. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from March 28, 2024 contingent upon the achievement of certain performance objectives, subject to the Reporting Person's continued service on each such vesting date.
4. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 24, 2026, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Teresa Jurgensen, Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does the Parabilis Medicines (PBLS) Form 3 filing for Mammen Mathai show?

The Form 3 shows Mammen Mathai’s existing stock option holdings in Parabilis Medicines. It details multiple options over common stock, including exercise prices, expiration dates, and vesting schedules tied to continued service and, for one grant, performance objectives.

How many Parabilis Medicines (PBLS) shares underlie Mammen Mathai’s $3.14 stock option?

One stock option block has an exercise price of $3.14 per share and covers 2,274,351 underlying common shares. This option expires in 2036, and related footnotes describe vesting conditions based on continued service with Parabilis Medicines.

What are the key terms of the $1.48 stock options reported in the PBLS Form 3?

Two option positions carry a $1.48 exercise price, covering 590,940 and 592,463 underlying common shares. Both expire in 2034 and vest in 48 equal monthly installments starting March 28, 2024, subject to Mammen Mathai’s continued service with the company.

Are any Parabilis Medicines (PBLS) options tied to performance objectives in this filing?

Yes. One $1.48 stock option grant vests in 48 monthly installments starting March 28, 2024, but is contingent on achieving specified performance objectives. Vesting also requires Mammen Mathai’s continued service with Parabilis Medicines on each applicable vesting date.

When do Mammen Mathai’s reported Parabilis Medicines stock options expire?

The reported stock options expire on various dates in 2033, 2034, and 2036. Specifically, one grant expires April 20, 2033, two expire March 27, 2034, and another expires February 23, 2036, providing long-dated equity incentives.

How do the Parabilis Medicines (PBLS) options for Mammen Mathai vest over time?

One grant vested 25% on March 16, 2024, with the remainder vesting monthly thereafter. Others vest in 48 equal monthly installments beginning March 28, 2024, or February 24, 2026, all subject to continued service and, for one grant, performance conditions.